Trump Accelerates Psychedelic Research

In a significant shift in federal drug policy, President Donald Trump has authorized a new initiative to fast-track research into psychedelic therapies.

The executive order focuses on substances such as ibogaine and psilocybin, which have been designated as potential breakthrough treatments for mental health disorders despite their current status as illegal drugs.

Trump signed the order in the Oval Office alongside Joe Rogan, who has been a vocal advocate for the therapeutic benefits of these substances.

The administration aims to provide new options for veterans struggling with depression and post-traumatic stress.